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Abstract 
Aims 
Cytokeratin 19 (CK19) mRNA copy number predicts the probability of tumour load in axillary lymph 
nodes (ALN) and can help in decision-making regarding the axillary dissection. The purpose of this 
study was to define a new cut-off of CK19 mRNA copy number using the one-step nucleic acid 
amplification (OSNA) assay on metastatic sentinel lymph nodes (SLN) in order to identify cases at 
risk of having one or more positive ALN. 
Methods 
1296 SLN from 1080 patients were analysed with the OSNA assay. 194 patients with positive SLN 
underwent ALN dissection and the mean value of CK19 copy number (320000) of their SLN was 
set as initial cut-off. Receiver operative characteristics curve identify a best cut-off of 7700 
(sensitivity 78%, specificity 57%). A comparison between our and the traditional cut-off (5000) was 
performed. 
Results 
The cut-off of 7700 successfully identifies patients with positive ALN (p=0.001, false- negative 
cases: 17%). In the range between 5000 and 7700, one patient with positive ALN would not 
undergo axillary dissection, whereas eight patients with negative ALN would be correctly identified. 
Conclusions 
We suggest that the level of CK19 mRNA copy number could be the only parameter to consider in 
the intraoperative management of the axilla. 
Introduction 
Since the end of 1990s, sentinel lymph node (SLN) biopsy has replaced traditional axillary lymph 
node (ALN) dissection and has become the standard technique for nodal staging in patients with 
breast cancer (BC) and clinically-negative axilla.1–4 Among patients with positive SLNs, ALN 
dissection (ALND) is the standard of care;5–7 however, it has been recently discussed whether 
ALND can be avoided in patients at low risk of metastasis in ALN.8 ,9 Many nomograms have been 
proposed in order to predict the likelihood of ALN positivity,10 ,11 but all of these are based on 
specific features concerning the primary tumour, such as size, histotype, grading, lymphovascular 
invasion, multifocality, oestrogen and progesterone receptors, Her2 neu overexpression, and 
molecular subtypes.11 Since in most of the Breast Cancer Units the preoperative management of 
BC is based on fine-needle aspiration biopsy,12 the information needed for nomograms are 
available only after surgery of the primary tumour. 
 
Since 2007, one-step nucleic acid amplification (OSNA) has been approved as a diagnostic 
semiautomatic system for lymph node examination.13 OSNA is an accurate tool for intraoperative 
assessment of the SLN status and quantitatively measures the presence of cytokeratin 19 (CK19) 
mRNA copy number, which, using predefined cut-offs,13 distinguishes the absence of metastasis 
(less than 250 CK19 mRNA copies) from the presence of either micrometastasis (250–5000 CK19 
mRNA copies or >0.2–2mm in diameter) or macrometastasis (more than 5000 CK19 mRNA copies 
or >2mm in diameter) (Union Internationale Contre le Cancer (UICC) Classification).14 
Until now, about 30 studies have been published demonstrating the reliability of the molecular 
OSNA assay in BC routine clinical practice.15–21 Among these, the study of Buglioni et al22 
demonstrated that a specific cut-off of 2000 CK19 mRNA copy numbers in the SLN could predict 
the likelihood of finding positive ALN, identifying patients who are eligible for ALND. This copy 
number was obtained from the molecular analysis of only a part of the SLN: indeed, this cut-off 
was based on a 4-slice model and only half of the SLN was used for OSNA. In addition, OSNA 
results were merged with histological and molecular variables of the BC subtypes, available only 
after surgery in the definitive surgical specimen.22 
In this study, we tried to define a specific cut-off of CK19 mRNA copy number, useful in clinical 
practice. Indeed, below this cut-off, the risk of positive non-SLN should be low and thus ALND 
could be omitted, independently of the characteristics of the primary tumour. 
Methods 
Study population 
This retrospective study included 1296 SLNs from 1080 patients (figure 1) with BC operated in 
three different hospitals between January 2009 and December 2012, in whom presurgical 
ultrasound and/or clinical examination as well as fine-needle aspiration biopsy of the axilla were 
negative. Patients (a) without any immunohistochemical expression of CK19 on the core biopsy of 
primary tumour, (b) with previous breast or axillary surgery or (c) receiving neoadjuvant 
chemotherapy were excluded from the study. In all the cases, breast surgery and SLN were 
performed. Tumours were graded according to Elston and Ellis grading system and staged 
according to the UICC tumour node metastasis system criteria.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Diagram of patients’ recruitment. SLN, sentinel lymph node; ALN, axillary lymph node; OSNA, one-step nucleic acid 
amplification. 
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Intraoperative SLN analysis with the OSNA assay 
The identification of SLN was performed by injection of a radioactive (99mTc-labelled nanocolloid) 
tracer at the level of the tumour and Patent Blue retroareolar. SLNs were removed surgically using 
a handheld γ-ray detection probe. SLNs were excised before primary tumour surgery and 
immediately sent on ice to pathology units for examination. The mean number of SLNs was 1.2 per 
patient. The fresh SLNs were harvested from the fat tissue, weighted and cut along the short axis 
to obtain gross sections of 2.0 mm thickness. Following the standard procedure for OSNA analysis 
described by Tsujimoto et al,13 SLN with a weight less than 50 mg were excluded from the study. 
The mean number of SLNs excluded from the study for the low weight was two per centre. SLNs 
weighting more than 600  mg were cut into two or more pieces and processed as separate 
samples. Imprint cytology was performed by touching the two sides of the cut surface of each 
gross section onto slides. Two of these slides were then fixed in methanol and stained with rapid 
H&E, and tested by rapid immunocytochemistry with anti-AE1/AE3 antibodies. Whole SLNs were 
examined by OSNA as previously described.13 Results were expressed as CK19 mRNA copy 
number per microlitre, and metastatic load was assessed in accordance with the cut-off levels 
defined by Tsujimoto et al:13 (+) symbol was defined as ‘micrometastases’ and the (++) symbol 
was defined as ‘macrometastases’. A negative result was defined as (−). 
Management of the ALNs after OSNA results 
ALND was not performed in patients with negative SLN (<250 mRNA copy number). Complete 
ALND was performed during the same surgical session in all patients with macrometastasis in 
SLN. Patients with micrometastasis underwent immediately ALND only in two of the three 
institutions; in one, ALND was delayed after a multidisciplinary discussion concerning clinical and 
biomorphological features of primary BC. 
Axillary non-SLNs were routinely examined by H&E staining and the number of positive lymph 
nodes was recorded. 
Informed consent was obtained from all patients before inclusion in the current protocol for the 
whole SLN examination by OSNA assay. The main clinical and pathological characteristics of the 
population studied are summarised in table 1. 
Table 1 
Clinical and pathological findings of 194 patients with positive sentinel lymph node who underwent 
axillary dissection 
 
Characteristics Patients (n#194) Percentage 
Median age (range) 60.1 (31–89) years / 
Histotype 
Ductal  150 77.3 
Lobular  30 15.5 
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Characteristics Patients (n#194) Percentage 
Other  14 7.2 
Grading 
1  27 13.9 
2  114 58.8 
3  47 24.2 
Unknown 6 3.1 
Tumour size 
T1  103 53.1 
T2  77 39.7 
T3  4 2 
Unknown  10 5.2 
Vascular invasion 
Absent  78 40.2 
Present  116 59.8 
Oestrogen receptor 
Negative  32 16.5 
Positive  162 83.5 
Progesterone receptor 
Negative  19 9.8 
Positive  175 90.2 
HER2 status 
Negative  173 89.2 
Positive  21 10.8 
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Statistical analysis 
Statistical analysis was performed using MedCalc statistical software, V.12.7.3 (MedCalc Software 
bvba, Ostend, Belgium). The association between categorical variables was determined using the 
χ2 or Fisher's exact test. Receiver operative characteristics (ROC) curves and Youden's index 
were performed in order to identify a new cut-off value. p Values of <0.05, with a 95% CI, were 
considered statistically significant. 
Results 
OSNA assay results and management of the axilla 
On the whole, SLNs of 840 patients (77.8%) were negative with the OSNA assay and 240 (22.2%) 
were positive. Among these, 123 (51.2%) had micrometastasis and 117 (48.8%) macrometastasis; 
194 patients underwent ALND, including all the patients with macrometastasis and 77 (77/123; 
62.6%) patients with micrometastasis. In patients undergoing ALND, 125 (125/194; 64.4%) did not 
have any additional metastatic lymph nodes in ALN, whereas one or more positive ALNs were 
detected in 69 patients (69/194; 35.6%) (figure 1). 
Correlation between CK19 mRNA copy number in positive SLN and the risk of axillary 
involvement 
First, we calculated the mean value of CK19 mRNA copy number in all the positive SLNs of the 
patients who underwent ALND, independently to the distinction between micrometastasis and 
macrometastasis. The CK19 mRNA copy number ranged from 250 to 7400000; the mean value of 
320000 CK19 mRNA copies was used as cut-off in order to distinguish patients with a high and low 
risk of metastasis in ALN. In the group of patients with a CK19 mRNA copy number higher than 
320000 in SLN, 55.2% had one or more positive ALN (true-positive), whereas in patients with a 
CK19 copy number less than 320000 in SLN, 32.2% had one or more positive ALN (false-
negative). Although the difference was statistically significant (p=0.021, table 2), the number of 
false-negative cases (53/165, 32%) was too high, probably related to the wide range of CK19 
mRNA copy numbers and therefore not useful in clinical practice. In order to overcome the 
limitation of this result, we used the ROC curve analysis23 to search for an optimal cut-off value 
with the highest sensitivity and specificity (figure 2). Across various cut-off points, Youden's index 
maximised the difference between sensitivity and specificity and between real-positive and false-
positive subjects; thus, the optimal cut-off value was calculated. The total sum of sensitivity and 1-
specificity of the single copy number cut-offs was represented by the ROC analysis, with a higher 
area under the curve (AUC) indicating the best cut-off for our objective. On the basis of ROC 
analysis, with an AUC of 0.69, the value for a cut-off was calculated to 7700 CK19 mRNA copies. 
Therefore, two groups were identified. The first group included 86 patients having ≤7700 of CK19 
mRNA copies: 71 (82.6%) were ALN-negative and 15 (17.4%) ALN-positive, with one or more 
positive lymph nodes (false-negative cases, table 2). The main pathological findings of these 15 
patients are reported in table 3. Except for patient 2, the CK19 mRNA copy number was always 
under 5000 copies, meaning that these cases would have been considered false-negative also 
using the classical cut-off of Tsujimoto et al.13 Interestingly, in four cases (n# 2, 7, 8 and 12), more 
than two additional ALNs were positive (pN2, table 3). The second group included 108 patients 
with more than 7700 CK19 mRNA copies; 54 (true-positive, 50%) were ALN-positive (p=0.001, 
table 2). The new cut-off showed 78% sensitivity and 57% specificity in differentiating patients with 
negative ALN or with one or more metastatic lymph nodes (table 4). Positive and negative 
predictive values of this new cut-off were 50% and 83%, respectively. 
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Table 2 
Comparison between ALN s status of 194 patients and the cut-off obtained by: (A) mean value of 
CK19 mRNA copy number in all positive SLN, (B) ROC curve and (C) according to Tsujimoto et 
al13 
 
 
 ALN+69 (%) ALN—125 (%) p Value χ2 
A 
Cut-off (no distinction micrometastases/macrometastases) 
≤320 000 (165) 53 (32.2) 112 (67.8) 0.02 5.719 
 >320 000 (29) 16 (55.2) 13 (44.8)   
B 
New cut-off (ROC curve) 
≤7700 (86)  15 (17.4) 71 (82.6) <0.001 22.145 
 >7700 (108) 54 (50) 54 (50)   
C 
Tsujimoto's cut-off 
≤5000 (77)  14 (18.2) 63 (81.8) <0.001 16.839 
 >5000 (117) 55 (47) 62 (53)   
 
Table 3 
Main pathological features of the 15 cases with a cytokeratin 19 (CK19) mRNA copy number 
≤7700 and one or more metastatic axillary lymph nodes 
 
 CK19 mRNA (copy/µL) Histotype Grading 
Tumour 
size 
SLN 
pos 
non-
SLN 
pos 
LVI Oestrogen receptor % PgR% 
HER2 
status Ki67%
1 3.60E+02 Ductal G2 pT1 1 1 Absent 100 100 Neg 10 
2 4.70E+02 Lobular G2 pT1 1 3 Present 95 75 Neg 4 
3 4.90E+02 Ductal G2 pT1 1 1 Present 99 70 Neg 14 
4 9.30E+02 Other G2 pT2 1 1 Absent 0 0 Pos 20 
5 1.30E+03 Ductal G2 pT1 1 1 Absent 95 82 Neg 14 
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 CK19 mRNA (copy/µL) Histotype Grading 
Tumour 
size 
SLN 
pos 
non-
SLN 
pos 
LVI Oestrogen receptor % PgR% 
HER2 
status Ki67%
6 1.70E+03 Ductal G3 pT1 1 1 Present 80 30 Neg 70 
7 2.10E+03 Ductal G2 pT1 1 4 Absent 100 100 Neg 10 
8 2.10E+03 Lobular G3 pT1 1 3 Absent 95 0 Neg 30 
9 2.50E+03 Ductal G2 pT1 1 1 Absent 0 0 Pos 40 
10 2.50E+03 Ductal G2 pT2 1 1 Absent 100 70 Neg 10 
11 2.70E+03 Lobular G1 pT1 1 1 Absent 100 80 Neg 14 
12 2.80E+03 Lobular G3 pT3 1 4 Present 90 35 Neg 42 
13 3.10E+03 Other G2 Unknown 1 1 Absent 20 10 Neg 5 
14 4.10E+03 Ductal G2 pT2 1 1 Absent 100 100 Neg 12 
15 7.40E+03 Ductal G2 pT2 1 1 Absent 95 38 Neg 32 
 
 
 
 
Table 4 
Comparison between the cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node 
proposed by Tsujimoto et al13 and our cut-off 
 
 
 
 Tsujimoto's cut-off (5000) (%) Our cut-off (7700) (%) 
Positive predictive value 47 50 
Negative predictive value 82 83 
Sensibility 80 78 
Specificity 50 57 
False-negative cases 18 17 
False-positive cases 53 50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
The new best cut-off of cytokeratin 19 mRNA copy number obtained by receiver operative characteristics curve analysis. 
 
Evaluation of the comparison between the traditional cut-off and the new cut-off value 
Finally, our case series was further analysed by using the classical cut-off of 5000 CK19 mRNA 
copy number proposed by Tsujimoto et al.13 As shown in table 4, only one patient with CK19 
mRNA copy number between 5000 and 7700 had one or more positive ALN, whereas eight 
patients had negative ALN. 
Discussion 
The OSNA assay allows the intraoperative determination of the SLN tumour load as a basis for 
decision-making in order to perform surgical axillary dissection.15–19 Moreover, CK19 mRNA copy 
number, associated with histological parameters (such as vascular invasion, receptor expression) 
and molecular subtypes (luminal A, luminal B, HER2-positive, triple-negative), correlates with the 
risk of tumour metastasis in other ALN, as recently demonstrated by Buglioni et al.22 
Our study took its origin essentially from two considerations: (a) OSNA assay is able to 
differentiate micrometastasis and macrometastasis using criteria derived from histology13 ,14 and 
(b) in the majority of Breast Cancer Units, presurgical investigations of BC are currently obtained 
by means of cytological examination12 and therefore neither histological parameters nor molecular 
subtypes of BC are available before surgery. Starting from the idea that the bidimensional 
histological distinction of micrometastasis and macrometastasis in SLN might not fully reflect a 
molecular tridimensional concept and an SLN intraoperative assay can be really useful in decisions 
concerning axillary dissection,15–18 we constructed an analysis to assess the risk of positive ALN in 
correlation with CK19 mRNA copy number in SLN as detected by OSNA, without further distinction 
in micrometastasis or macrometastasis. 
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Our case series consisted of 1296 SLNs from 1080 BC patients; among these, 194 ALNDs were 
performed following positive OSNA results (micrometastasis or macrometastasis). This group of 
patients was the object of the study. The 194 cases with positive SNL showed a PR positivity rate 
slightly higher than ER positivity rate (90.2% vs 83.5%). This finding, quite unusual for breast 
carcinoma, could be explained with the lack of uniformity in the preanalytical phase, staining 
procedure or in the use of different antibodies among the three centres. 
Using the cut-off obtained from the mean value of CK19 mRNA copy number in all the SLN-
positive patients, independently by the distinction in micrometastasis or macrometastasis, our 
results had statistical significance for the cut-off value of 320000 CK19 mRNA copy number. 
Unfortunately, this result was clinically unsatisfactory because of the high percentage of false-
negative cases (32%), meaning that, using this cut-off, the surgical treatment would not have been 
applied to more than a third of the patients with positive ALN. Moreover, the mean value was 
modified by the presence of high levels of CK19 mRNA copy number in some lymph nodes; indeed 
in our range, very high values (millions copy) of CK19 copy number were included, suggesting that 
there was a wrong presurgical selection during the axillary ultrasound or clinical examination in a 
few cases. 
To overcome the limitation of this model, we constructed a ROC curve23 to establish the best cut-
off value in term of sensitivity and specificity allowing us to identify patients with one or more 
positive non-SLN. We found that the value of 7700 CK19 mRNA copies may be useful to this aim; 
however, 18% of patients were classified as false-negative. These cases were separately analysed 
in order to search for any other factors associated with this metastatic profile. Interestingly, 
considering the CK19 mRNA copy number, 14 out of 15 cases were diagnosed as micrometastasis 
by OSNA, meaning that in the majority of the Breast Units, these patients would not have done any 
additional ALND. In addition, three patients had more than three positive ALNs (pN2) and, among 
these, two were lobular carcinoma, further confirming the need of a more careful follow-up for this 
histotype. 
The current cut-off of Tsujimoto and collegues13 that identifies macrometastasis is settled as 5000 
copies/uL; for this cut-off value generally, there is still a strong uniformity in surgery, as patients 
with macrometastatic SLN are still now always operated in Italy, differently from micrometastasis. 
We have implemented a comparison between our cut-off derived from the calculation with ROC 
curves23 and the cut-off of Tsujimoto and coworkers;13 our data were analysed according to both 
the cut-offs. Below 5000 CK19 mRNA copies in SLN, 14 patients had a positive ALN and 63 a 
negative ALN. Below 7700 copies (our cut-off) in SLN, 15 patients had a positive ALN and 71 a 
negative ALN. Thus, the further step to our cut-off demonstrates that only one patient with positive 
ALN would not have been profited from a complete surgical dissection, but eight patients with 
negative ALN would not have been submitted to a useless operation on the axilla. Compared with 
the current cut-off established by Tsujimoto et al,13 our cut-off had higher specificity to identify 
patients who do not need axillary dissection. Our cut-off identifies better false-positive and false-
negative cases and true-positive and true-negative cases, addressing more precisely to the 
complete surgery patients who really need the ALND from patients who can avoid it. Heilmann et al 
found that a cut-off CK19 mRNA copy number of 7900/μL obtained using ROC analysis indicates a 
positive non-SLN result with the highest sensitivity and specificity.24 This result was obtained by 
processing separately 1 mm middle slice for histology and the rest for OSNA, and therefore it might 
not represent the real copy number of CK19 mRNA of the entire lymph node. 
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The OSNA assay is an optimal molecular approach to define a rapid diagnosis of SLN status.15–18 It 
allows an intraoperative decision about the surgical management of the patients without the need 
of presurgical histological parameters such as the tumour subtypes.15 On the other hand, the 
histological concept of micrometastasis and macrometastasis should be abandoned in favour of an 
objective evaluation of CK19 mRNA copy number. 
The proposed cut-off value of 7700 CK19 mRNA copies may represent a useful tool in the 
selection of patients in which ALND could be recommended due to the risk of having additional 
metastatic ALN. Prospective studies are needed to determine the clinical impact of this variable in 
the management of BC patients. 
Take home messages 
The decision of performing axillary lymph node dissection in breast cancer relies on the status of 
the sentinel lymph node treated by histological or molecular approach. The distinction between 
micrometastasis and macrometastasis in sentinel lymph node, based on established cut-offs (2 
mm or 5000 copy number of cytokeratin 19 (CK19) mRNA), helps surgeons to identify patients 
eligible for axillary lymph node dissection, but some of the patients with micrometastasis could be 
undertreated. 
A recently proposed cut-off of 2000 copy number of CK19 mRNA, along with histological and 
molecular features of the breast cancer, could better identify patients with high risk for axillary 
lymph node metastasis. Since these findings are available only after surgery in breast cancer units 
using fine-needle aspiration biopsy as preoperative management, these data have only a limited 
clinical application. 
Using a receiver operative characteristics curve analysis, we calculated the best cut-off of 7700 
copy number of CK19 mRNA obtained by one-step nucleic acid amplification examination of 
metastatic sentinel lymph node independently to the distinction between micrometastasis and 
macrometastasis and the findings of primary tumour. This cut-off identifies successfully patients 
with positive axillary lymph nodes with a low negative rate, suggesting that the level of CK19 
mRNA copy number could be the only parameter to consider in the intraoperative management of 
the axilla. 
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